Select Page

Alpha Pharma and SAP sign deal for digital transformation partnership

Alpha Pharma and SAP sign deal for digital transformation partnership

SAP’s suite of solutions deliver initial steps into wider digitalization strategy

Riyadh, Saudi Arabia — 28 March 2022 — Alpha Pharma, a local pharmaceutical manufacturer with the state-of-the-art manufacturing facility, and a part of the leading healthcare distributor Cigalah healthcare company in Saudi Arabia, has inked a partnership with global technology company SAP to enable its digital transformation as part of a wider business strategy.

The new partnership aims to streamline Alpha Pharma’s operations in the areas of finance, supply chain, logistics, production, and HR, while also aligning the organization with the digitalization goals of Saudi Vision 2030. Recognizing the benefits of a digitalized management approach, Alpha Pharma plans to deploy solutions including SAP S/4HANA, SuccessFactor, Private Cloud and the core offering of RISE with SAP to centralize and streamline a number of key business functions.

Murad Al-Saggaf, General Manager, Alpha Pharma_ssict_1200_1258

Commenting on the partnership, Murad Al-Saggaf, General Manager, Alpha Pharma said: “Just as technology plays a significant role in our nation’s Vision 2030, Alpha Pharma recognizes the cost efficiencies and organizational agility that can be achieved through digital transformation.  SAP’s demonstrated expertise and knowledge of Saudi Arabia make them an ideal partner for Alpha Pharma on this organization-wide journey.”

Mohammed Alromaizan, SAP KSA Vice President, said: “We have previously successfully implemented business solutions for global healthcare and pharmaceutical brands which have given us greater insight into Alpha Pharma’s digital transformation potential. In addition to the partnership, this signing also helps SAP further strengthen our presence in the Kingdom’s pharmaceutical sector.”

Established in 2017, Alpha Pharma is a subsidiary of Cigalah healthcare company with a direct investment of SAR 296 million. The pharmaceutical plant boasts the capacity to produce up to 1 billion tablets, 300 million capsules and 30 million bottles of syrups and suspensions per year that complies with international Current Good Manufacturing Practice cGMP standards. The plant also maintains high quality across manufacturing stages while focusing on continues improvement and minimal operator intervention.

About The Author

Latest News


WP Twitter Auto Publish Powered By :